ASCO 2016: Keane's Corner blog - Bladder Cancer.

Thomas Keane, Editor-in-Chief UroToday.com, discusses new treatment advances for patients with metastatic urothelial cancer.  The standard of care for patients with locally advanced or metastatic urothelial cancer is currently cisplatin-based chemotherapy, which is the only therapy ever shown to improve survival in this setting. However, nearly half of patients diagnosed with this disease will not be eligible for cisplatin-based therapy due to poor renal function, performance status, or other medical problems, which render the therapy too toxic. For these patients, we commonly use carboplatin-based therapy, which is considered less toxic. However, it is less efficacious. Regardless, for the vast majority of patients, the cancer will progress despite this therapy. And, in the second-line setting, there are no approved treatments and survival is very poor.  New treatment advances for this patient population have been being investigated.  In May 2016 atezolizumab—branded Tecentriq, a new cancer immunotherapy was approved by the FDA. 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe